Natera presented data at the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting showing strong clinical performance of its Panorama SNP-based non-invasive prenatal test to detect common chromosomal aneuploidies in all women, including women under 35 years of age, with high accuracy. The primary objective of the study was to prospectively analyze the clinical performance of the company’s NIPT as a part of its rigorous laboratory-based quality assurance program. Fetal outcome data was solicited from women who received a high-risk result from over 900,000 Panorama tests performed between 2013 and 2017. The positive predictive value in this cohort was 95.2% for trisomy 21, 93.5% for trisomy 18, 77.9% for trisomy 13, and 86.7% for monosomy X. The PPV was similar for both high-risk and average risk pregnancies, consistent with a previous study. “The high positive predictive values demonstrated in this study once again validate the utility of NIPT as a primary prenatal screening tool in the management of all pregnancies, including women under 35 years of age,” said Dr. Kimberly A. Martin, Natera Vice President, Global Women’s Health. “We believe this study continues to reaffirm NIPT as the most accurate screening option for pregnant women of all ages.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.